Yauch
Lauren Yauch, La Jolla, CA US
Patent application number | Description | Published |
---|---|---|
20130202634 | Dengue Virus (DV) Polypeptide Sequences, T Cell Epitopes and Methods and Uses Thereof - Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8 | 08-08-2013 |
Laurene E. Yauch, La Jolla, CA US
Patent application number | Description | Published |
---|---|---|
20110150914 | COMPOSITIONS AND METHODS FOR DENGUE VIRUS (DV) TREATMENT AND VACCINATION - The invention relates to Dengue virus (DV) peptides and compositions thereof, and methods that employ Dengue virus (DV) peptides and compositions thereof. The invention includes among other things, methods of treating Dengue virus (DV) infection or pathology, which include, for example, administering Dengue virus (DV) peptide T cell epitope, to treat a Dengue virus (DV) infection or pathology. The invention includes among other things Dengue virus (DV) vaccination and immunization methods. | 06-23-2011 |
Robert L. Yauch, Redwood City, CA US
Patent application number | Description | Published |
---|---|---|
20090155807 | C-MET MUTATIONS IN LUNG CANCER - The invention provides methods and compositions useful for detecting mutations in c-met in lung cancer cells. | 06-18-2009 |
20120089541 | BIOMARKERS AND METHODS OF TREATMENT - The present invention concerns cancer biomarkers. In particular, the invention concerns c-met as biomarkers for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto. | 04-12-2012 |
20120282259 | MUTANT SMOOTHENED AND METHODS OF USING THE SAME - The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance. | 11-08-2012 |
20140037625 | BIOMARKERS AND METHODS OF TREATMENT - The present invention concerns cancer biomarkers. In particular, the invention concerns c-met as biomarkers for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto. | 02-06-2014 |
20150056207 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer. | 02-26-2015 |
Robert L. Yauch, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20120157480 | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors - The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided. | 06-21-2012 |
Steven S. Yauch, Clayton, NC US
Patent application number | Description | Published |
---|---|---|
20130259749 | METHODS, DEVICES, SYSTEMS, AND COMPOSITIONS FOR DETECTING GASES - A method of monitoring a respiratory stream can be provided by monitoring color change of a color change material to determine a CO2 level of the respiratory stream in contact with the color change material by emitting visible light onto the color change material. Related devices, systems, and compositions are also disclosed. | 10-03-2013 |